New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

July 16, 2002

Primary Completion Date

May 25, 2004

Study Completion Date

May 25, 2004

Conditions
Infection, Human Immunodeficiency Virus IHIV Infection
Interventions
DRUG

abacavir/lamivudine

DRUG

abacavir

DRUG

lamivudine

DRUG

tenofovir

Trial Locations (76)

1000

GSK Investigational Site, Brussels

2750

GSK Investigational Site, Cascais

3000

GSK Investigational Site, Leuven

4000

GSK Investigational Site, Liège

8400

GSK Investigational Site, Barcelona

10149

GSK Investigational Site, Turin

10468

GSK Investigational Site, The Bronx

11794

GSK Investigational Site, Stony Brook

19102

GSK Investigational Site, Philadelphia

19131

GSK Investigational Site, Philadelphia

20099

GSK Investigational Site, Hamburg

20157

GSK Investigational Site, Milan

23666

GSK Investigational Site, Hampton

25125

GSK Investigational Site, Brescia

28040

GSK Investigational Site, Madrid

28047

GSK Investigational Site, Madrid

28209

GSK Investigational Site, Charlotte

29600

GSK Investigational Site, Marbella

30159

GSK Investigational Site, Hanover

30308

GSK Investigational Site, Atlanta

30339

GSK Investigational Site, Atlanta

30625

GSK Investigational Site, Hanover

30912

GSK Investigational Site, Augusta

32206

GSK Investigational Site, Jacksonville

32804

GSK Investigational Site, Orlando

32806

GSK Investigational Site, Orlando

33140

GSK Investigational Site, Miami Beach

33145

GSK Investigational Site, Fort Lauderdale

33308

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

33317

GSK Investigational Site, Plantation

33602

GSK Investigational Site, Tampa

33901

GSK Investigational Site, Fort Myers

37135

GSK Investigational Site, Verona

41100

GSK Investigational Site, Modena

44100

GSK Investigational Site, Ferrara

44304

GSK Investigational Site, Akron

46202

GSK Investigational Site, Indianapolis

60590

GSK Investigational Site, Frankfurt am Main

63108

GSK Investigational Site, St Louis

69437

GSK Investigational Site, Lyon

70115

GSK Investigational Site, New Orleans

75204

GSK Investigational Site, Dallas

75208

GSK Investigational Site, Dallas

75651

GSK Investigational Site, Paris

80335

GSK Investigational Site, Munich

90046

GSK Investigational Site, Los Angeles

92300

GSK Investigational Site, Levallois-Perret

92380

GSK Investigational Site, Garches

94275

GSK Investigational Site, Le Kremlin-Bicêtre

94602

GSK Investigational Site, Oakland

98104

GSK Investigational Site, Seattle

30308/30309

GSK Investigational Site, Atlanta

29206-4713

GSK Investigational Site, Columbia

V6Z 1Y6

GSK Investigational Site, Vancouver

K1N 6N5

GSK Investigational Site, Ottawa

M4N 3M5

GSK Investigational Site, Toronto

M5B 1W8

GSK Investigational Site, Toronto

M5G 2C4

GSK Investigational Site, Toronto

H2L 4P9

GSK Investigational Site, Montreal

H2L 5B1

GSK Investigational Site, Montreal

G1V 4G2

GSK Investigational Site, Sainte-Foy

4700-308

GSK Investigational Site, Braga

3000-075

GSK Investigational Site, Coimbra

8000-386

GSK Investigational Site, Faro

1769-001

GSK Investigational Site, Lisbon

Unknown

GSK Investigational Site, Lisbon

08036

GSK Investigational Site, Barcelona

03202

GSK Investigational Site, Elche (Alicante)

M8 5RB

GSK Investigational Site, Manchester

CR7 7YE

GSK Investigational Site, Thornton Heath

NW3 2QG

GSK Investigational Site, London

SE5 9RS

GSK Investigational Site, London

SW10 9TH

GSK Investigational Site, London

SW17 0QT

GSK Investigational Site, London

W2 1NY

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY